Accelerating Cancer Cures is a multi-million-dollar project that will train a new generation of exceptional clinical investigators capable of translating the latest scientific discoveries into new diagnostics and therapeutics for patients. The initiative also fosters communication and collaboration between academia and industry. Accelerating Cancer Cures is sponsored by some of the world’s leading companies: Eli Lilly and Company, Celgene, Genentech, Merck, Novartis, and Pfizer.
Accelerating Cancer Cures is supported by leading biopharmaceutical companies who are committed to finding new cures for cancer. The charter participants are: Eli Lilly and Company, Celgene, Genentech, Merck, and Pfizer. Competitors in the marketplace, these companies have a shared belief that funding young physician-scientists with a commitment to innovation in cancer research will have a profound impact on the next generation of cancer breakthroughs.